The Wockhardt Group, formerly a prominent player in the pharmaceutical industry, is facing financial challenges. With mounting debts and a struggling business, the group's valuable assets are now headed to market. This dramatic turn of events has sent shockwaves through the industry, spurring speculation within financial circles. It remains unknow